#1 Clinical Trials Search in Europe

Bepranemab

Bepranemab, also known as UCB0107, is an investigational drug being studied for the treatment of Progressive Supranuclear Palsy (PSP). This article explores the ongoing clinical trials that are evaluating the safety, tolerability, and potential effectiveness of Bepranemab in patients with PSP. These trials aim to provide valuable insights into this promising treatment option for a challenging neurological condition.

Table of Contents

What is Bepranemab?

Bepranemab, also known as UCB0107, is an investigational drug currently being studied for its potential in treating Progressive Supranuclear Palsy (PSP)[1][2]. It is important to note that this medication is still in the research phase and is not yet approved for general use. Researchers are conducting clinical trials to determine its effectiveness and safety for patients with PSP.

What Condition Does Bepranemab Target?

Progressive Supranuclear Palsy (PSP) is the primary condition that bepranemab aims to treat[1][2]. PSP is a rare brain disorder that affects movement, balance, and eye control. It is a progressive condition, meaning it worsens over time. Patients with PSP may experience difficulties with walking, balance, speech, swallowing, and eye movements. Currently, there is no cure for PSP, which makes research into potential treatments like bepranemab particularly important.

How is Bepranemab Administered?

Based on the information from the clinical trials, bepranemab is administered in the following way[1][2]:

  • Form: Solution for infusion (a liquid medication that is given directly into the bloodstream)
  • Route of Administration: Intravenous (IV) – This means the medication is given through a vein, typically in the arm
  • Dosage: The exact dosage is described as “predefined” in the trials, which means it has been carefully determined by researchers but may vary depending on the specific study or patient needs

This method of administration allows the medication to be delivered directly into the bloodstream, potentially maximizing its effectiveness in reaching the brain where it’s needed to target PSP symptoms.

Current Clinical Trials

There are currently two main clinical trials investigating bepranemab for PSP[1][2]:

  1. Long-term Safety and Tolerability Study: This is an open-label extension study, which means all participants receive the actual drug (no placebo). The study aims to assess the long-term safety and tolerability of bepranemab in patients with PSP over a period of 60 months (5 years)[1].
  2. Phase 1b Safety, Tolerability, and Pharmacokinetics Study: This is a participant-blind and investigator-blind, placebo-controlled study. It aims to evaluate the safety, tolerability, and pharmacokinetics (how the drug moves through the body) of bepranemab in PSP patients. This study lasts for 68 weeks and includes a placebo group for comparison[2].

These trials are crucial steps in determining whether bepranemab could be a safe and effective treatment for PSP in the future.

Safety and Tolerability

The primary focus of both clinical trials is to assess the safety and tolerability of bepranemab in patients with PSP[1][2]. Researchers are closely monitoring for any adverse events (AEs), which are any unintended medical occurrences in patients receiving the drug. These could include:

  • Unintended diseases or injuries
  • Untoward clinical signs (including abnormal laboratory findings)
  • Any unfavorable signs or symptoms associated with the use of the drug

It’s important to understand that the occurrence of adverse events doesn’t necessarily mean they are caused by the drug, but all such events are carefully recorded and analyzed to ensure patient safety. The long-term study will monitor these events for up to 5 years, providing valuable information about the drug’s safety profile over an extended period[1].

In conclusion, while bepranemab shows promise as a potential treatment for Progressive Supranuclear Palsy, it is still in the research phase. The ongoing clinical trials will provide crucial information about its safety, tolerability, and effectiveness. Patients with PSP and their caregivers should keep in touch with their healthcare providers for the latest updates on potential new treatments like bepranemab.

Aspect Details
Drug Name Bepranemab (UCB0107)
Condition Studied Progressive Supranuclear Palsy (PSP)
Administration Method Intravenous infusion
Primary Outcome Measure Incidence of treatment emergent adverse events (TEAEs)
Study Types Open-label extension and Placebo-controlled
Study Durations Up to 60 months (long-term) and up to 68 weeks
Main Study Objectives Assess safety, tolerability, and long-term effects

FAQ

  • What is Bepranemab? Bepranemab, also known as UCB0107, is an investigational drug being studied for the treatment of Progressive Supranuclear Palsy (PSP). It is administered intravenously as a solution for infusion.
  • What is the main purpose of the clinical trials involving Bepranemab? The main purpose of these clinical trials is to assess the safety and tolerability of Bepranemab in patients with Progressive Supranuclear Palsy. The studies also aim to evaluate the long-term effects of the drug.
  • How is Bepranemab administered in the clinical trials? In the clinical trials, Bepranemab is administered intravenously as a solution for infusion. The drug is given in predefined dosages to the study participants.
  • What is the duration of these clinical trials? The duration of the trials varies. One study mentions a timeframe of up to 60 months (5 years) for long-term evaluation, while another study has a duration of up to 68 weeks.
  • How do researchers measure the safety of Bepranemab in these trials? Researchers measure the safety of Bepranemab by monitoring the incidence of treatment emergent adverse events (TEAEs). These are any unintended medical occurrences that happen during the study period, whether or not they are related to the drug being tested.

Ongoing Clinical Trials on Bepranemab

  • Study on Bepranemab for Patients with Early Alzheimer’s Disease

    Not recruiting

    2 1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +1

  • Study on the Long-Term Safety of Bepranemab for Adults with Progressive Supranuclear Palsy

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Germany Spain

Glossary

  • Progressive Supranuclear Palsy (PSP): A rare brain disorder that causes problems with movement, balance, speech, swallowing, vision, mood and behavior, and thinking. It is a progressive condition, meaning symptoms worsen over time.
  • Bepranemab: An investigational drug, also known as UCB0107, being studied for the treatment of Progressive Supranuclear Palsy. It is administered intravenously as a solution for infusion.
  • Intravenous: A method of administering medication directly into a vein, allowing it to enter the bloodstream immediately.
  • Placebo: A substance that has no active ingredients and is used in clinical trials to compare the effects of a new drug. In these trials, it's a solution of 0.9% sodium chloride in water.
  • Treatment Emergent Adverse Events (TEAEs): Any unfavorable and unintended sign, symptom, or disease that occurs during the use of a medicinal product in a clinical study, whether or not it is related to the product being tested.
  • Open-Label Extension Study: A type of clinical trial where both the researchers and participants know which treatment is being administered, often conducted after a controlled trial to gather long-term data.
  • Randomization: The process of randomly assigning participants to different treatment groups in a clinical trial to reduce bias.
  • Pharmacokinetics: The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.

References